Habermann W, Eherer A, Lindbichler F, Raith J, Friedrich G
Department of ENT, Internal Medicine, University of Graz, Medical School, Austria.
J Laryngol Otol. 1999 Aug;113(8):734-9. doi: 10.1017/s0022215100145050.
The aim of this study was to investigate whether patients with chronic posterior laryngitis and symptoms of gastro-pharyngeal reflux benefit from a six-week therapy with pantoprozole. Twenty-nine out-patients with voice disorders (case history of at least two months) and simultaneous symptoms of gastro-pharyngeal reflux were recruited for this study. At the entry to the study a symptom questionnaire and a video-laryngo/stroboscopy were completed. The symptom questionnaire and the video-laryngo/stroboscopy were repeated after the six weeks of therapy with pantoprazole 40 mg once a day and again six weeks and three months after this follow-up, during which time the patient was without therapy. Hoarseness, globus pharyngeus, sore throat, heartburn, and coughing were the symptoms which showed a significant (p < 0.05) recovery at the follow-ups (mean of hoarseness index: 7.28 to 0.92; mean of globus pharyngeus index: 3.14 to 0.58; mean of heartburn index: 2.86 to 0.5; mean of cough index: 1.72 to 0.25; mean of throat soreness index: 1.72 to 0.15). Laryngoscopy scores of the posterior laryngeal region, the glottic and the supraglottic region showed statistically significant improvement (p < 0.05) after the treatment with pantoprazole. The therapeutic effect exceeded the drug administration until the last follow-up (after three months). The medication was tolerated without side-effects in all patients. A primary (ex juvantibus) therapy with proton pump inhibitors seems to be a therapeutic option for patients with long-lasting chronic inflammation of the larynx not responding to common therapy. In this case a six-week course of treatment has been shown to be sufficient.
本研究的目的是调查患有慢性喉炎且有胃咽反流症状的患者是否能从泮托拉唑六周疗法中获益。29名患有嗓音障碍（病史至少两个月）且同时伴有胃咽反流症状的门诊患者被纳入本研究。在研究开始时，完成了一份症状问卷和一次视频喉镜/频闪喉镜检查。在用泮托拉唑40毫克每日一次进行六周治疗后，以及在此次随访后的六周和三个月再次进行随访时（在此期间患者未接受治疗），重复进行症状问卷和视频喉镜/频闪喉镜检查。声音嘶哑、咽部异物感、咽痛、烧心和咳嗽等症状在随访时显示出显著（p < 0.05）改善（声音嘶哑指数均值：从7.28降至0.92；咽部异物感指数均值：从3.14降至0.58；烧心指数均值：从2.86降至0.5；咳嗽指数均值：从1.72降至0.25；咽痛指数均值：从1.72降至0.15）。喉后部区域、声门和声门上区域的喉镜评分在用泮托拉唑治疗后显示出统计学上的显著改善（p < 0.05）。治疗效果在最后一次随访（三个月后）前一直超过药物给药期。所有患者对该药物耐受性良好，无副作用。对于对常规治疗无反应的长期慢性喉炎患者，质子泵抑制剂的一线（经验性）治疗似乎是一种治疗选择。在这种情况下，已证明六周的疗程就足够了。
